Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms

In patients with BCR-ABL-negative myeloproliferative neoplasms (MPN), arterial or venous thromboembolic events (ATE/VTE) are a major burden. In order to control these complications, vitamin K antagonists (VKA) are widely used. There is no robust evidence supporting the use of direct oral anticoagula...

Descripción completa

Detalles Bibliográficos
Autores principales: Huenerbein, Karlo, Sadjadian, Parvis, Becker, Tatjana, Kolatzki, Vera, Deventer, Eva, Engelhardt, Carina, Griesshammer, Martin, Wille, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285319/
https://www.ncbi.nlm.nih.gov/pubmed/33216197
http://dx.doi.org/10.1007/s00277-020-04350-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285319/
https://www.ncbi.nlm.nih.gov/pubmed/33216197
http://dx.doi.org/10.1007/s00277-020-04350-6

Ejemplares similares